Multibavger your clueless . Still don't get the difference between cash runway and what is needed to avoid a going concern qualification . Like many on this BB over the years very clued up on the science but when it comes to business and accounts sadly very lacking . The fund raises have kept coming as I predicted many many years ago,even when the bod and plenty of investors said they wouldn't . One more incoming imo before may watch this space |
Next week the share price will build strongly towards 17p
After we sign another contract or two we will easily be trading in the 20s
sent from my iPhone |
A clearer version.. |
Icopied and pasted the link no problem, thanks mesquida. Although I would not describe the rise as a "Surge". |
Lofty, this is not a link so cannot access the article, in a few brief words can you tell us what it says. Thanks in advance. |
https://i.dailymail.co.uk/1s/2025/01/24/21/94489731-14322641-image-a-11_1737753553374.jpg |
A while ago whilst responding to a question about the future of the company Andrew said one of three things will happen.1. Angle will become a large company 2. Angle will partner with a large company3. Angle will be bought by a large company.Think on that one. |
That is very vague. It could be Q1 in 2026.
The trading update in November 2023 stated we had a cash runway to Q2 2025.
By the beginning of June 2024 we had a cash call for 8.5 million and possible 2,000,000 to shareholders of which only half of a million was raised.
This was done as a 16.7% discount to the prevailing price, and 10 to 12 months before the cash runway was supposed to expire.
Think on that one. |
Cash runway till 2026 bone-idle. |
 waterloo01 - you may be right, personally I hope not but time will tell. UK Small Cap success stories are indeed historically speaking, a bit thin on the ground & by that I mean those that develop within the UK & continue to grow.
There are plenty of signs that Angle are forging strong relationships as perhaps can be illustrated here :
'Complementary insights: Exploring the dual analysis of circulating tumour cells and circulating DNA' EACR-Illumina webinar
Thursday 06 February 2025 | 17:00 – 18:00 CET
This public webinar is hosted in collaboration with Illumina, one of our valued EACR Industry Partners. In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients and she will discuss how dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care.
Click here to register (open to all, you do not need to be an EACR member to attend)."
Anne-Sophie Pailhes-Jimenez |
Someone, ie Illumina or Quigen or AZ will make them an offer. Long thought it... |
Decent volume today. Primarily on the back of the latest rns.
More to come and I suspect it'll continue to be a combination of new or extended contracts as well as trial results.
Interesting times that's for sure. |
Bones....maybe lauch another aliasIdea...bone idle. |
Lovely bowl chart forming over the 1 year So far we have these figures for the share price:Up 22% in 7 daysUp 40% on the monthUp 81% over 3 months |
Don't mind bones
He's still short
The next contract should be enough to squeeze him out at a hefty loss
sent from my iPhone |
Remember when adw sold all his shares thinking he was clever
Then we had PATT bones and all the other cronies talking the company down
What happened next? We saw 25p very quickly
History repeating
sent from my iPhone |
Cash runway to 2026. What are you on about bones?? |
Oh dear Bones. Been calling this a sell somce 7.5p. I would rather go by what the Co says, and its announcements through RNS rather than listen to someone like you, an anonymous poster on a bulletin board, clearly with axe to grind or trader sowing FUD.Imagine bones posting at 20 or 30p.Zero credibility |
Bone idle shows. What a plank. Use your other aliases too. #whataplank |
One is coming unless they can get an upfront payment form one of these deals soon . Yesterday's rns showed the cash position and they will want to avoid a going concern statement in the June results which will only be possible with more cash on the books . The broker note didn't show a huge uotick in likely revenues either so that's not going to do it leaving a fund raise highly probable in the next 2-4 months imo |
PATT, I disagree with your post, “Looks to me like they are trying to stimulate buying to get an equity raise done.” The trial results were just released, and it’s entirely reasonable for AN to highlight the pivotal role Parsortix played in this significant clinical trial.
This study was previously recognized by Nature Medicine as one of the 11 clinical trials poised to shape medicine in 2023. It’s a groundbreaking trial and warrants the attention it’s receiving. |
super - thanks for that and well spotted.
Nicola Aceto is one of the leading experts in the field and his lab has been set up purely to research and study circulating tumour cells to understand the metastatic process and develop therapies to prevent it. Research on CTCs is what they do and it's really encouraging that he has chosen the Parsortix system to install in his lab and for this research. The link below is to a short video and although it's old it's worth a look for any who may not be familiar with his work. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
